» Articles » PMID: 1327596

Comparison of the Pharmacokinetics and Pharmacodynamics of Perindopril, Cilazapril and Enalapril

Overview
Specialties Pharmacology
Physiology
Date 1992 Jan 1
PMID 1327596
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

1. The pharmacokinetic and pharmacodynamic responses to enalapril, perindopril and cilazapril have been studied in essential hypertensives (2, 4 and 8 mg perindopril and 2.5 mg cilazapril, single dose and steady state) and normotensive volunteers (10 mg enalapril, single dose). 2. Plasma levels of the active diacid compounds reached similar peaks after single dose administration of the drugs. However, perindoprilat levels persisted for 5 days whereas cilazaprilat levels were not detectable beyond 12 h. 3. The higher levels of perindoprilat were associated with a greater inhibition of plasma angiotensin-converting enzyme (ACE) activity in both acute and steady state studies. 4. The potency of the active diacids in inhibiting plasma ACE activity was perindoprilat greater than cilazaprilat greater than enalaprilat. 5. There was a close relationship between plasma concentration, ACE inhibition and blood pressure decrease. Although both cilazapril and perindopril administration reduced blood pressure in hypertensive subjects, only perindopril exerted 24 h blood pressure control at the doses used.

Citing Articles

Exercise-induced angiogenesis is attenuated by captopril but maintained under perindopril treatment in hypertensive rats.

Macedo A, Miotto D, Tardelli L, Santos C, Amaral S Front Physiol. 2023; 14:1147525.

PMID: 37284543 PMC: 10239938. DOI: 10.3389/fphys.2023.1147525.


Identification of Aortic Proteins Involved in Arterial Stiffness in Spontaneously Hypertensive Rats Treated With Perindopril:A Proteomic Approach.

Miotto D, Dionizio A, Jacomini A, Zago A, Buzalaf M, Amaral S Front Physiol. 2021; 12:624515.

PMID: 33679438 PMC: 7928294. DOI: 10.3389/fphys.2021.624515.


A Proline-Based Tectons and Supramolecular Synthons for Drug Design 2.0: A Case Study of ACEI.

Bojarska J, Remko M, Breza M, Madura I, Fruzinski A, Wolf W Pharmaceuticals (Basel). 2020; 13(11).

PMID: 33114370 PMC: 7692516. DOI: 10.3390/ph13110338.


Perindopril Induces TSP-1 Expression in Hypertensive Patients with Endothelial Dysfunction in Chronic Treatment.

Buda V, Andor M, Petrescu L, Cristescu C, Baibata D, Voicu M Int J Mol Sci. 2017; 18(2).

PMID: 28178210 PMC: 5343883. DOI: 10.3390/ijms18020348.


Comparative Solid-State Stability of Perindopril Active Substance vs. Pharmaceutical Formulation.

Buda V, Andor M, Ledeti A, Ledeti I, Vlase G, Vlase T Int J Mol Sci. 2017; 18(1).

PMID: 28098840 PMC: 5297797. DOI: 10.3390/ijms18010164.